These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25697572)

  • 1. Genome sequencing in myelodysplastic syndromes: can molecular mutations predict benefit from hypomethylating agent therapy?
    Lee EJ; Zeidan AM
    Expert Rev Hematol; 2015 Apr; 8(2):155-8. PubMed ID: 25697572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
    Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
    Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis.
    Du M; Zhou F; Jin R; Hu Y; Mei H
    Leuk Res; 2019 May; 80():11-18. PubMed ID: 30884372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
    Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
    Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.
    Jung SH; Kim YJ; Yim SH; Kim HJ; Kwon YR; Hur EH; Goo BK; Choi YS; Lee SH; Chung YJ; Lee JH
    Oncotarget; 2016 Aug; 7(34):55264-55275. PubMed ID: 27419369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
    Komrokji RS
    Am Soc Clin Oncol Educ Book; 2016; 35():e345-52. PubMed ID: 27249741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations and karyotype predict treatment response in myelodysplastic syndromes.
    Idossa D; Lasho TL; Finke CM; Ketterling RP; Patnaik MM; Pardanani A; Gangat N; Tefferi A
    Am J Hematol; 2018 Nov; 93(11):1420-1426. PubMed ID: 30152885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
    Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY
    Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic role of TET2 deficiency in myelodysplastic syndromes: A meta-analysis.
    Lin Y; Lin Z; Cheng K; Fang Z; Li Z; Luo Y; Xu B
    Oncotarget; 2017 Jun; 8(26):43295-43305. PubMed ID: 28476038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis.
    Cai L; Zhao X; Ai L; Wang H
    Clin Exp Med; 2020 Aug; 20(3):361-371. PubMed ID: 32613269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
    Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
    Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
    Wang R; Xu Y; Wang B; Wang H; Wang M; Jing Y; Gao X; Yu L
    Ann Hematol; 2024 Jan; 103(1):61-71. PubMed ID: 37926751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adding the epigenomic signature to the prognostic jigsaw of myelodysplastic neoplasm?
    Gill H
    Br J Haematol; 2024 May; 204(5):1577-1578. PubMed ID: 38563073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing hypomethylating agents in myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Curr Opin Hematol; 2012 Mar; 19(2):65-70. PubMed ID: 22248878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
    Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
    Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypomethylating agent based combinations in higher risk myelodysplastic syndrome.
    Chandhok NS; Lewis R; Prebet T
    Leuk Lymphoma; 2020 May; 61(5):1012-1027. PubMed ID: 31814484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel therapies for higher-risk myelodysplastic syndromes].
    Nannya Y
    Rinsho Ketsueki; 2018; 59(10):2058-2066. PubMed ID: 30305509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life after hypomethylating agents in myelodysplastic syndrome: new strategies.
    Santini V
    Curr Opin Hematol; 2015 Mar; 22(2):155-62. PubMed ID: 25603477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukaemia: recent data on prognostic gene mutations, in relation to stratified therapies for elderly patients.
    Soura EN; Karikas GA
    J BUON; 2019; 24(4):1326-1339. PubMed ID: 31646775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetics of myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Leukemia; 2014 Mar; 28(3):497-506. PubMed ID: 24247656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.